Phase 1 Data Reveals Soquelitinib Drives Durable Remission in Resistant Atopic Dermatitis
Corvus Pharmaceuticals unveiled final data from its randomized, placebo-controlled Phase 1 trial of soquelitinib at the Society for Investigative Dermatology (SID) Annual Meeting, highlighting the drug’s ability to induce prolonged, drug-free remissions in moderate-to-severe atopic dermatitis—including patients who failed prior therapies.
Efficacy Signals: High Remission Rates Achieved and Maintained Post-Treatment
The trial enrolled 72 adults who had not responded to at least one prior topical or systemic therapy. Key results from the most intensive dosing regimens (200 mg twice daily) were compelling:
| Cohort | Regimen | EASI 75 (%) | EASI 90 (%) | IGA 0/1 (%) |
|---|---|---|---|---|
| Cohort 3 | 200 mg BID, 28 days | 50 | 8 | 25 |
| Cohort 4 | 200 mg BID, 56 days | 75 | 25 | 33 |
Notably, the majority of patients maintained these responses after stopping therapy, with no evidence of disease rebound—unlike what is typically reported with approved systemic options.
Safety Profile Mirrors Placebo—with No Serious Adverse Events
Safety was equally encouraging, as adverse events occurred in 41.7% of both soquelitinib and placebo groups—all mild to moderate, requiring no dose modification or interruptions, and no serious lab abnormalities were observed.
Immunologic Markers Confirm Mechanism and Support Durable Remission
Soquelitinib’s design targets ITK in T cells, orchestrating a shift from inflammatory Th2/Th17 response toward regulatory T cell (Treg) dominance. The trial’s biomarker and molecular data confirmed:
- Sustained reduction in Th2/Th17 cytokines (IL-4, IL-5, IL-13, IL-17), persisting post-treatment
- Significant, persistent increases in Treg cells during and after therapy
- Inhibition of JAK-STAT signaling, upregulation of SOCS3, and decreased JAK1 and STAT6—all reinforcing the immune “rebalancing” effect
This constellation of immune changes matches the durable clinical remissions observed and highlights the drug's novel mechanism not directly targeted by current approved therapies.
Soquelitinib’s Profile Suggests a Transformative Potential in Immune Diseases
Due to its ability to provide durable, drug-free remission—particularly in patients resistant to other systemic options—soquelitinib may offer a significant advance for both patients and clinicians facing atopic dermatitis. This approach could also translate to broader autoimmune or allergic conditions.
Next Steps: Phase 2 Trials Underway with Broader Patient Cohorts
Corvus is progressing with the SIERRA1 Phase 2 randomized, placebo-controlled trial of soquelitinib, with four cohorts and multiple dosing regimens, aimed at enrolling about 200 patients with moderate-to-severe atopic dermatitis. A similar trial is ongoing in China in collaboration with Angel Pharmaceuticals, with results from initial cohorts expected later this year.
Key Takeaways
- Soquelitinib demonstrated robust, durable remissions and strong safety in Phase 1 atopic dermatitis patients—many of whom failed prior therapies.
- Immunologic and clinical evidence supports the potential for drug-free remission and immune rebalancing—uncommon among current therapies.
- Phase 2 trials are actively enrolling, with global data anticipated soon and possible readthrough to multiple immune-mediated diseases.
For further insights, the SID presentation slides and webcast replay are available on the Corvus Pharmaceuticals website.
Contact Information:
If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.
About the Publisher - Marketchameleon.com:
Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.
NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.
The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.
Disclosure: This article was generated with the assistance of AI